The Chemokine Receptor 5 Delta32 Polymorphism and Type 1 Diabetes, Behcet’s Disease, and Asthma: A Meta-analysis

References

• Abousaidi H, Vazirinejad R, Arababadi MK, et al. (2011). Lack of association between chemokine receptor 5 (CCR5) delta32 mutation and pathogenesis of asthma in Iranian patients. South Med J, 104, 422–5
   Google Scholar
• Al-Abdulhadi SA, Al-Rabia MW. (2010). Linkage and haplotype analysis for chemokine receptors clustered on chromosome 3p21.3 and transmitted in family pedigrees with asthma and atopy. Ann Saudi Med, 30, 115–22
   Google Scholar
• Al-Abdulhadi SA, Al-Rabia MW. (2011). Tests and estimates (transmission disequilibrium test) for allelic association of CCR5delta32 with asthma in high-risk families. J Pak Med Assoc, 61, 267–73
   Google Scholar
• Atzeni F, Boiardi L, Casali B, et al. (2012). CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. Rheumatology (Oxford), 51, 2141–5
   Google Scholar
• Becker KG. (1999). Comparative genetics of type 1 diabetes and autoimmune disease: Common loci, common pathways? Diabetes, 48, 1353–8
   PubMed Web of Science ®Google Scholar
• Becker KG. (2004). The common variants/multiple disease hypothesis of common complex genetic disorders. Med Hypotheses, 62, 309–17
   PubMed Web of Science ®Google Scholar
• Benkirane M, Jin DY, Chun RF, et al. (1997). Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem, 272, 30603–6
   PubMed Web of Science ®Google Scholar
• Bettencourt A, Carvalho C, Leal B, et al. (2010). The CC chemokine receptor polymorphism CCR5delta32 is not a genetic susceptibility factor for Behcnullet disease in the Portuguese population. Clinical Exper Rheumatol, 28, S165
   Google Scholar
• Boiardi L, Vaglio A, Nicoli D, et al. (2011). CC chemokine receptor 5 polymorphism in chronic periaortitis. Rheumatology (Oxford), 50, 1025–32
   PubMedGoogle Scholar
• Davey Smith G, Egger M. (1997). Meta-analyses of randomised controlled trials. Lancet, 350, 1182
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177–88
   PubMed Web of Science ®Google Scholar
• Dhaouadi T, Sfar I, Aounallah-Skhiri H, et al. (2013). MCP-1, CCR2 and CCR5 polymorphisms in Tunisian patients with atopic Asthma. Iran J Allergy Asthma Immunol, 12, 29–36
   Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. (1997). Bias in meta-analysis detected by a simple, graphical test. Br Med J, 315, 629–34
   PubMed Web of Science ®Google Scholar
• Gambelunghe G, Ghaderi M, Brozzetti A, et al. (2003). Lack of association of CCR2-64I and CCR5-Delta 32 with type 1 diabetes and latent autoimmune diabetes in adults. Hum Immunol, 64, 629–32
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539–58
   PubMed Web of Science ®Google Scholar
• Kalev I, Oselin K, Parlist P, et al. (2003). CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. J Diabetes Complications, 17, 387–91
   Google Scholar
• Kallaur AP, Kaimen-Maciel DR, Morimoto HK, et al. (2011). Genetic polymorphisms associated with the development and clinical course of multiple sclerosis (review). Int J Mol Med, 28, 467–79
   PubMed Web of Science ®Google Scholar
• Lee YH, Bae SC, Song GG. (2013). Association between the chemokine receptor 5 delta32 polymorphism and rheumatoid arthritis: A meta-analysis. Mod Rheumatol, 23, 304–10
   PubMedGoogle Scholar
• Lee YH, Harley JB, Nath SK. (2006). Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet, 14, 364–71
   PubMed Web of Science ®Google Scholar
• Lee YH, Rho YH, Choi SJ, et al. (2007). PADI4 polymorphisms and rheumatoid arthritis susceptibility: A meta-analysis. Rheumatol Int, 27, 827–33
   PubMed Web of Science ®Google Scholar
• Lee YH, Song GG. (2012). Associations between eNOS polymorphisms and susceptibility to Behcet's disease: A meta-analysis. J Eur Acad Dermatol Venereol, 26, 1266–71
   Google Scholar
• Lee YH, Witte T, Momot T, et al. (2005). The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: Two case-control studies and a meta-analysis. Arthritis Rheum, 52, 3966–74
   PubMed Web of Science ®Google Scholar
• Liu R, Paxton WA, Choe S, et al. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell, 86, 367–77
   PubMed Web of Science ®Google Scholar
• Maier-Moore JS, Canas CA, Tobon G, et al. (2013). The CCR5 delta 32 polymorphism (rs333) is not associated with Sjogren's syndrome or Type 1 Diabetes in Colombians. Clin Immunol, 148, 206–8
   Google Scholar
• Marrack P, Kappler J, Kotzin BL. (2001). Autoimmune disease: Why and where it occurs. Nat Med, 7, 899–905
   PubMed Web of Science ®Google Scholar
• Mitchell TJ, Walley AJ, Pease JE, et al. (2000). Delta 32 deletion of CCR5 gene and association with asthma or atopy. Lancet, 356, 1491–2
   PubMed Web of Science ®Google Scholar
• Mlynarski WM, Placha GP, Wolkow PP, et al. (2005). Risk of diabetic nephropathy in type 1 diabetes is associated with functional polymorphisms in RANTES receptor gene (CCR5): A sex-specific effect. Diabetes, 54, 3331–5
   PubMed Web of Science ®Google Scholar
• Mojtahedi Z, Ahmadi SB, Razmkhah M, et al. (2006). Association of chemokine receptor 5 (CCR5) (Delta)32 mutation with Behcet's disease is dependent on gender in Iranian patients. Clin Exper Rheumatol, 24, S91–4
   Google Scholar
• Nath SK, Harley JB, Lee YH. (2005). Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: A meta-analysis. Hum Genet, 118, 225–34
   PubMed Web of Science ®Google Scholar
• Paxton WA, Kang S. (1998). Chemokine receptor allelic polymorphisms: Relationships to HIV resistance and disease progression. Semin Immunol, 10, 187–94
   PubMedGoogle Scholar
• Prahalad S. (2006). Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: A meta-analysis. Genes Immun, 7, 264–8
   PubMed Web of Science ®Google Scholar
• Sakane T, Takeno M, Suzuki N, Inaba G. (1999). Behcet's disease. N Engl J Med, 341, 1284–91
   PubMed Web of Science ®Google Scholar
• Sandford AJ, Zhu S, Bai TR, et al. (2001). The role of the C-C chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. J Allergy Clin Immunol, 108, 69–73
   Google Scholar
• Smyth DJ, Plagnol V, Walker NM, et al. (2008). Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med, 359, 2767–77
   PubMed Web of Science ®Google Scholar
• Szalai C, Csaszar A, Czinner A, et al. (1999). Chemokine receptor CCR2 and CCR5 polymorphisms in children with insulin-dependent diabetes mellitus. Pediatr Res, 46, 82–4
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Kim J, Koch AE. (2003). Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol, 15, 15–21
   PubMed Web of Science ®Google Scholar
• Turner JE, Paust HJ, Steinmetz OM, et al. (2008). CCR5 deficiency aggravates crescentic glomerulonephritis in mice. J Immunol, 181, 6546–56
   Google Scholar
• Wu L, LaRosa G, Kassam N, et al. (1997). Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med, 186, 1373–81
   PubMed Web of Science ®Google Scholar
• Yang B, Houlberg K, Millward A, Demaine A. (2004). Polymorphisms of chemokine and chemokine receptor genes in Type 1 diabetes mellitus and its complications. Cytokine, 26, 114–21
   PubMed Web of Science ®Google Scholar
• Yang X, Ahmad T, Gogus F, et al. (2004). Analysis of the CC chemokine receptor 5 (CCR5) Delta32 polymorphism in Behcet's disease. Eur J Immunogenet, 31, 11–4
   PubMedGoogle Scholar
• Zhou Y, Huang D, Farver C, Hoffman GS. (2003). Relative importance of CCR5 and antineutrophil cytoplasmic antibodies in patients with Wegener's granulomatosis. J Rheumatol, 30, 1541–7
   PubMedGoogle Scholar